CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in investment for the research and development of psychedelic drugs.
3.4.1.2. Increased social acceptance of psychedelic drugs.
3.4.1.3. Rise in prevalence of mental illness.
3.4.2. Restraints
3.4.2.1. Safety concerns regarding the use of psychedelic drugs
3.4.3. Opportunities
3.4.3.1. Rise in awareness about mental health
CHAPTER 4: PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Ketamine
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Psilocybin
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: PSYCHEDELIC DRUGS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Mental Health
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Abuse Disorder
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: PSYCHEDELIC DRUGS MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Mental Health Center
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: PSYCHEDELIC DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Drug Type
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Drug Type
7.2.5.1.2. Market size and forecast, by Application
7.2.5.1.3. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Drug Type
7.2.5.2.2. Market size and forecast, by Application
7.2.5.2.3. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Drug Type
7.2.5.3.2. Market size and forecast, by Application
7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Drug Type
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Drug Type
7.3.5.1.2. Market size and forecast, by Application
7.3.5.1.3. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Drug Type
7.3.5.2.2. Market size and forecast, by Application
7.3.5.2.3. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Drug Type
7.3.5.3.2. Market size and forecast, by Application
7.3.5.3.3. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Drug Type
7.3.5.4.2. Market size and forecast, by Application
7.3.5.4.3. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Drug Type
7.3.5.5.2. Market size and forecast, by Application
7.3.5.5.3. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Drug Type
7.3.5.6.2. Market size and forecast, by Application
7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Drug Type
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. Market size and forecast, by Drug Type
7.4.5.1.2. Market size and forecast, by Application
7.4.5.1.3. Market size and forecast, by End User
7.4.5.2. Japan
7.4.5.2.1. Market size and forecast, by Drug Type
7.4.5.2.2. Market size and forecast, by Application
7.4.5.2.3. Market size and forecast, by End User
7.4.5.3. Australia
7.4.5.3.1. Market size and forecast, by Drug Type
7.4.5.3.2. Market size and forecast, by Application
7.4.5.3.3. Market size and forecast, by End User
7.4.5.4. Rest of Asia-Pacific
7.4.5.4.1. Market size and forecast, by Drug Type
7.4.5.4.2. Market size and forecast, by Application
7.4.5.4.3. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Drug Type
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Drug Type
7.5.5.1.2. Market size and forecast, by Application
7.5.5.1.3. Market size and forecast, by End User
7.5.5.2. South Africa
7.5.5.2.1. Market size and forecast, by Drug Type
7.5.5.2.2. Market size and forecast, by Application
7.5.5.2.3. Market size and forecast, by End User
7.5.5.3. Rest of LAMEA
7.5.5.3.1. Market size and forecast, by Drug Type
7.5.5.3.2. Market size and forecast, by Application
7.5.5.3.3. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Numinus Wellness Inc
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Enveric Biosciences
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.3. Field Trip Health
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.4. Johnson & Johnson (J&J)
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Havn Life
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Key strategic moves and developments
9.6. PharmaTher
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Key strategic moves and developments
9.7. Psyched Wellness
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Key strategic moves and developments
9.8. Apex Labs
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.9. Ceruvia Lifesciences
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.10. Braxia Scientific
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
TABLE 01. GLOBAL PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 02. PSYCHEDELIC DRUGS MARKET FOR KETAMINE, BY REGION, 2022-2032 ($MILLION)
TABLE 03. PSYCHEDELIC DRUGS MARKET FOR PSILOCYBIN, BY REGION, 2022-2032 ($MILLION)
TABLE 04. PSYCHEDELIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 06. PSYCHEDELIC DRUGS MARKET FOR MENTAL HEALTH, BY REGION, 2022-2032 ($MILLION)
TABLE 07. PSYCHEDELIC DRUGS MARKET FOR ABUSE DISORDER, BY REGION, 2022-2032 ($MILLION)
TABLE 08. PSYCHEDELIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 10. PSYCHEDELIC DRUGS MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. PSYCHEDELIC DRUGS MARKET FOR MENTAL HEALTH CENTER, BY REGION, 2022-2032 ($MILLION)
TABLE 12. PSYCHEDELIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. PSYCHEDELIC DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 18. U.S. PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 19. U.S. PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 20. U.S. PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 21. CANADA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 22. CANADA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 23. CANADA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 24. MEXICO PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 25. MEXICO PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 26. MEXICO PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 27. EUROPE PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 28. EUROPE PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 29. EUROPE PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 30. EUROPE PSYCHEDELIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 31. GERMANY PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 32. GERMANY PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 33. GERMANY PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 34. FRANCE PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 35. FRANCE PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 36. FRANCE PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 37. UK PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 38. UK PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 39. UK PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 40. ITALY PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 41. ITALY PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 42. ITALY PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 43. SPAIN PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 44. SPAIN PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 45. SPAIN PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 53. CHINA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 54. CHINA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 55. CHINA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 56. JAPAN PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 57. JAPAN PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 58. JAPAN PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 59. AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 60. AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 62. REST OF ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 63. REST OF ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 64. REST OF ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 65. LAMEA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 66. LAMEA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 67. LAMEA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 68. LAMEA PSYCHEDELIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 69. BRAZIL PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 70. BRAZIL PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 71. BRAZIL PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 72. SOUTH AFRICA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 73. SOUTH AFRICA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 74. SOUTH AFRICA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 75. REST OF LAMEA PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 76. REST OF LAMEA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 77. REST OF LAMEA PSYCHEDELIC DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 78. NUMINUS WELLNESS INC: KEY EXECUTIVES
TABLE 79. NUMINUS WELLNESS INC: COMPANY SNAPSHOT
TABLE 80. NUMINUS WELLNESS INC: PRODUCT SEGMENTS
TABLE 81. NUMINUS WELLNESS INC: PRODUCT PORTFOLIO
TABLE 82. ENVERIC BIOSCIENCES: KEY EXECUTIVES
TABLE 83. ENVERIC BIOSCIENCES: COMPANY SNAPSHOT
TABLE 84. ENVERIC BIOSCIENCES: PRODUCT SEGMENTS
TABLE 85. ENVERIC BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 86. FIELD TRIP HEALTH: KEY EXECUTIVES
TABLE 87. FIELD TRIP HEALTH: COMPANY SNAPSHOT
TABLE 88. FIELD TRIP HEALTH: PRODUCT SEGMENTS
TABLE 89. FIELD TRIP HEALTH: PRODUCT PORTFOLIO
TABLE 90. JOHNSON & JOHNSON (J&J): KEY EXECUTIVES
TABLE 91. JOHNSON & JOHNSON (J&J): COMPANY SNAPSHOT
TABLE 92. JOHNSON & JOHNSON (J&J): PRODUCT SEGMENTS
TABLE 93. JOHNSON & JOHNSON (J&J): PRODUCT PORTFOLIO
TABLE 94. JOHNSON & JOHNSON (J&J): KEY STRATERGIES
TABLE 95. HAVN LIFE: KEY EXECUTIVES
TABLE 96. HAVN LIFE: COMPANY SNAPSHOT
TABLE 97. HAVN LIFE: PRODUCT SEGMENTS
TABLE 98. HAVN LIFE: PRODUCT PORTFOLIO
TABLE 99. HAVN LIFE: KEY STRATERGIES
TABLE 100. PHARMATHER: KEY EXECUTIVES
TABLE 101. PHARMATHER: COMPANY SNAPSHOT
TABLE 102. PHARMATHER: PRODUCT SEGMENTS
TABLE 103. PHARMATHER: PRODUCT PORTFOLIO
TABLE 104. PHARMATHER: KEY STRATERGIES
TABLE 105. PSYCHED WELLNESS: KEY EXECUTIVES
TABLE 106. PSYCHED WELLNESS: COMPANY SNAPSHOT
TABLE 107. PSYCHED WELLNESS: PRODUCT SEGMENTS
TABLE 108. PSYCHED WELLNESS: PRODUCT PORTFOLIO
TABLE 109. PSYCHED WELLNESS: KEY STRATERGIES
TABLE 110. APEX LABS: KEY EXECUTIVES
TABLE 111. APEX LABS: COMPANY SNAPSHOT
TABLE 112. APEX LABS: PRODUCT SEGMENTS
TABLE 113. APEX LABS: PRODUCT PORTFOLIO
TABLE 114. CERUVIA LIFESCIENCES: KEY EXECUTIVES
TABLE 115. CERUVIA LIFESCIENCES: COMPANY SNAPSHOT
TABLE 116. CERUVIA LIFESCIENCES: PRODUCT SEGMENTS
TABLE 117. CERUVIA LIFESCIENCES: PRODUCT PORTFOLIO
TABLE 118. BRAXIA SCIENTIFIC: KEY EXECUTIVES
TABLE 119. BRAXIA SCIENTIFIC: COMPANY SNAPSHOT
TABLE 120. BRAXIA SCIENTIFIC: PRODUCT SEGMENTS
TABLE 121. BRAXIA SCIENTIFIC: PRODUCT PORTFOLIO
